Early fast-acting treatment strategy against generalized myasthenia gravis

Kimiaki Utsugisawa; Yuriko Nagane; Tetsuya Akaishi; Yasushi Suzuki; Tomihiro Imai; Emiko Tsuda; Naoya Minami; Akiyuki Uzawa; Naoki Kawaguchi; Masayuki Masuda; Shingo Konno; Hidekazu Suzuki; Hiroyuki Murai; Masashi Aoki

doi:10.1002/mus.25397

Early fast-acting treatment strategy against generalized myasthenia gravis

Kimiaki Utsugisawa, Yuriko Nagane, Tetsuya Akaishi, Yasushi Suzuki, Tomihiro Imai, Emiko Tsuda, Naoya Minami, Akiyuki Uzawa, Naoki Kawaguchi, Masayuki Masuda, Shingo Konno, Hidekazu Suzuki, Hiroyuki Murai, Masashi Aoki

Research output: Contribution to journal › Article › peer-review

36 Citations (Scopus)

Abstract

Introduction: In this study we sought to clarify the effects of early fast-acting treatment (EFT) strategies on the time course for achieving the treatment target in generalized myasthenia gravis (MG). Methods: This retrospective study of 923 consecutive MG patients analyzed 688 generalized MG patients who had received immunotherapy during the disease course. The time to first achieve minimal manifestations (MM) or better while receiving prednisolone at ≤5 mg/day for ≥6 months (MM-or-better-5mg) up to 120 months after starting immunotherapy was compared between EFT and non-EFT patients. Results: Achievement of MM-or-better-5mg was more frequent and earlier in the EFT group (P = 0.0004, Wilcoxon test; P = 0.0001, log-rank test). Multivariate Cox regression analysis calculated a hazard ratio of 1.98 (P < 0.0001) for utilization of EFT. Dosing regimens of oral steroids in EFT produced no differences in the time course. Conclusions: EFT strategies are advantageous for early achievement of MM-or-better-5mg. Muscle Nerve 55: 794–801, 2017.

Original language	English
Pages (from-to)	794-801
Number of pages	8
Journal	Muscle and Nerve
Volume	55
Issue number	6
DOIs	https://doi.org/10.1002/mus.25397
Publication status	Published - Jun 2017
Externally published	Yes

All Science Journal Classification (ASJC) codes

Physiology
Clinical Neurology
Cellular and Molecular Neuroscience
Physiology (medical)

Access to Document

10.1002/mus.25397

Cite this

@article{6e8b29f333ff420c84e8be4fbdefa0e5,

title = "Early fast-acting treatment strategy against generalized myasthenia gravis",

abstract = "Introduction: In this study we sought to clarify the effects of early fast-acting treatment (EFT) strategies on the time course for achieving the treatment target in generalized myasthenia gravis (MG). Methods: This retrospective study of 923 consecutive MG patients analyzed 688 generalized MG patients who had received immunotherapy during the disease course. The time to first achieve minimal manifestations (MM) or better while receiving prednisolone at ≤5 mg/day for ≥6 months (MM-or-better-5mg) up to 120 months after starting immunotherapy was compared between EFT and non-EFT patients. Results: Achievement of MM-or-better-5mg was more frequent and earlier in the EFT group (P = 0.0004, Wilcoxon test; P = 0.0001, log-rank test). Multivariate Cox regression analysis calculated a hazard ratio of 1.98 (P < 0.0001) for utilization of EFT. Dosing regimens of oral steroids in EFT produced no differences in the time course. Conclusions: EFT strategies are advantageous for early achievement of MM-or-better-5mg. Muscle Nerve 55: 794–801, 2017.",

author = "Kimiaki Utsugisawa and Yuriko Nagane and Tetsuya Akaishi and Yasushi Suzuki and Tomihiro Imai and Emiko Tsuda and Naoya Minami and Akiyuki Uzawa and Naoki Kawaguchi and Masayuki Masuda and Shingo Konno and Hidekazu Suzuki and Hiroyuki Murai and Masashi Aoki",

note = "Publisher Copyright: {\textcopyright} 2016 The Authors. Muscle & Nerve Published by Wiley Periodicals, Inc.",

year = "2017",

month = jun,

doi = "10.1002/mus.25397",

language = "English",

volume = "55",

pages = "794--801",

journal = "Muscle and Nerve",

issn = "0148-639X",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Early fast-acting treatment strategy against generalized myasthenia gravis

AU - Utsugisawa, Kimiaki

AU - Nagane, Yuriko

AU - Akaishi, Tetsuya

AU - Suzuki, Yasushi

AU - Imai, Tomihiro

AU - Tsuda, Emiko

AU - Minami, Naoya

AU - Uzawa, Akiyuki

AU - Kawaguchi, Naoki

AU - Masuda, Masayuki

AU - Konno, Shingo

AU - Suzuki, Hidekazu

AU - Murai, Hiroyuki

AU - Aoki, Masashi

PY - 2017/6

Y1 - 2017/6

N2 - Introduction: In this study we sought to clarify the effects of early fast-acting treatment (EFT) strategies on the time course for achieving the treatment target in generalized myasthenia gravis (MG). Methods: This retrospective study of 923 consecutive MG patients analyzed 688 generalized MG patients who had received immunotherapy during the disease course. The time to first achieve minimal manifestations (MM) or better while receiving prednisolone at ≤5 mg/day for ≥6 months (MM-or-better-5mg) up to 120 months after starting immunotherapy was compared between EFT and non-EFT patients. Results: Achievement of MM-or-better-5mg was more frequent and earlier in the EFT group (P = 0.0004, Wilcoxon test; P = 0.0001, log-rank test). Multivariate Cox regression analysis calculated a hazard ratio of 1.98 (P < 0.0001) for utilization of EFT. Dosing regimens of oral steroids in EFT produced no differences in the time course. Conclusions: EFT strategies are advantageous for early achievement of MM-or-better-5mg. Muscle Nerve 55: 794–801, 2017.

AB - Introduction: In this study we sought to clarify the effects of early fast-acting treatment (EFT) strategies on the time course for achieving the treatment target in generalized myasthenia gravis (MG). Methods: This retrospective study of 923 consecutive MG patients analyzed 688 generalized MG patients who had received immunotherapy during the disease course. The time to first achieve minimal manifestations (MM) or better while receiving prednisolone at ≤5 mg/day for ≥6 months (MM-or-better-5mg) up to 120 months after starting immunotherapy was compared between EFT and non-EFT patients. Results: Achievement of MM-or-better-5mg was more frequent and earlier in the EFT group (P = 0.0004, Wilcoxon test; P = 0.0001, log-rank test). Multivariate Cox regression analysis calculated a hazard ratio of 1.98 (P < 0.0001) for utilization of EFT. Dosing regimens of oral steroids in EFT produced no differences in the time course. Conclusions: EFT strategies are advantageous for early achievement of MM-or-better-5mg. Muscle Nerve 55: 794–801, 2017.

UR - http://www.scopus.com/inward/record.url?scp=85013113051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013113051&partnerID=8YFLogxK

U2 - 10.1002/mus.25397

DO - 10.1002/mus.25397

M3 - Article

AN - SCOPUS:85013113051

SN - 0148-639X

VL - 55

SP - 794

EP - 801

JO - Muscle and Nerve

JF - Muscle and Nerve

IS - 6

ER -

Early fast-acting treatment strategy against generalized myasthenia gravis

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this